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Background
Reverse transcriptase, the viral enzyme, is a key target in
the search for effective drugs useful for AIDS therapy
and has critical roles in the life cycle of the human
immunodeficiency virus type 1 (HIV-1), the causative
agent of AIDS. HIV replication can be blocked by inhi-
bition of the enzyme HIV RT.
Method
The object of our study is to develop newer nucleoside
phosphonate analogs bearing unsaturation and modifica-
tions in heterogenous bases and prediction of their anti-
HIV potential. Designing is done keeping the Lipinski’s
Rule of Five in focus. The diphosphates of compounds
have been docked into the active site of wild type HIV-
RT (PDB: ID 2B6A). The forcefield of the Chemistry at
Harvard Macromolecular mechanics (CHARMm) was
applied to 3D models of PD HIV RT-nevirapine com-
plex and synthesized ligands. The energy function is
based on separable internal coordinate terms and pair
wise non-bond interaction terms.
Result
Docking studies revealed that the diphosphates of acyc-
lic phosphonates had good interactions with various
amino acid residues present in the active site of HIV
RT. The Ludi 3 score was found to be 718 and the cor-
responding Kd value was 0.06µM. This is in good agree-
ment with the observed value of 0.05µM.
Conclusion
On the basis of SAR studies, uridine phosphonate ana-
logs are expected to be probable lead molecules against
HIV-RT.
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